With a child dying from malaria every two minutes and the threat of drug resistance growing year-on-year, there is a real urgency to step up global efforts to combat this disease.
Joe Jimenez, CEO of Novartis
For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.
The Novartis Malaria Initiative is focused on conducting research and development for the next generation of antimalarials, improving access to treatment and helping communities deliver better healthcare. Operated by Sandoz, the Novartis generics and biosimilars division, the Malaria Initiative is one of the pharmaceutical industry's largest access-to-medicine programs. Since 2001, the initiative has delivered more than 800 million treatments without profit, including 300 million dispersible pediatric treatments, mostly to the public sector of malaria-endemic countries.
Read more about the Malaria Initiative
1. WHO World Malaria Report 2015. Available at: http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.pdf?... (link is external)
2. World Health Organization. http://www.who.int/mediacentre/factsheets/fs094/en/ (link is external)